Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus

Drug Resistance Updates

Volumn 14, Issue 1, 2011, Pages 45-51

  Field, Hugh J ^a   Biswas, Subhajit ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMENAMEVIR; ANTIVIRUS AGENT; BAY 57 1293; BAY 571293; BILS 179BS; DNA POLYMERASE; HELICASE; HELICASE PRIMASE INHIBITOR; PENCICLOVIR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VALACICLOVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CROSS RESISTANCE; DNA REPLICATION; DRUG EFFICACY; DRUG TARGETING; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOCOMPROMISED PATIENT; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DNA HELICASES; DNA PRIMASE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 79951955901     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.11.002     Document Type: Article

References (51)

1. Aicuris. www.aicuris.com, 09 November 2009.
2. G. Andrei, P. Fiten, E. De Clercq, R. Snoeck, and G. Opdenakker Evaluating phenotype and genotype of drug-resistant strains in herpesvirus Mol. Biotechnol. 18 2001 155 167 (Pubitemid 32646246)
3. J. Baumeister, R. Fischer, P. Eckenberg, K. Henninger, H. Ruebsamen-Waigmann, and G. Kleymann Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease Antivir. Chem. Chemother. 18 2007 35 48 (Pubitemid 46426936)
4. U.A.K. Betz, R. Fischer, G. Kleymann, M. Hendrix, and H. Rübsamen-Waigmann Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY57-1293 Antimicrob. Agents Chemother. 46 2002 1766 1772 (Pubitemid 34535195)
5. S. Biswas, and H.J. Field Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations Antivir. Chem. Chemother. 19 2008 1 6
6. Biswas, S., Field, H.J. (in press). Helicase-primase inhibitors - a new approach to combating herpes simplex and varicella-zoster viruses. In: E. De Clercq (Ed.), Antiviral Drug Strategies, Whiley.
7. S. Biswas, L. Jennens, and H.J. Field The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1 Antivir. Res. 75 2007 30 35 (Pubitemid 46621066)
8. S. Biswas, L. Jennens, and H.J. Field Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture Arch. Virol. 152 2007 1489 1500 (Pubitemid 47124949)
9. S. Biswas, G. Kleymann, M. Swift, L. Tiley, J. Lyall, J. Aguirre-Hernández, and H.J. Field A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target J. Antimicrob. Chemother. 61 2008 1044 1047 (Pubitemid 351524447)
10. S. Biswas, R.N. Muguel, S. Sukla, and H.J. Field A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure J. Gen. Virol. 90 2009 1937 1942
11. S. Biswas, C. Smith, and H.J. Field Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in two of ten recent clinical isolates of HSV-1 J. Antimicrob. Chemother. 60 2007 274 279 (Pubitemid 47243874)
12. S. Biswas, M. Swift, and H.J. Field High frequency of spontaneous helicase primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1 Antivir. Chem. Chemother. 18 2007 13 23 (Pubitemid 46426934)
13. S. Biswas, L.S. Tiley, H. Zimmermann, A. Birkmann, and H.J. Field Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity Antivir. Res. 80 2008 81 85
14. N.A. Cavanaugh, K.A. Ramirez-Aguilar, M. Urban, and R.D. Kuchta Herpes simplex virus-1 helicase-primase: roles of each subunit in DNA binding and phosphodiester bond formation Biochemistry 48 2009 10199 10207
15. K. Chono, K. Katsumata, T. Kontani, M. Kobayashi, K. Sudo, T. Yokota, K. Konno, Y. Shimizu, and H. Suzuki ASP2151 a novel helicase-primase inhibitor, possesses antiviral 1 activity against varicella-zoster virus and herpes simplex virus types 1 and 2 J. Antimicrob. Chemother. 65 2010 1733 1741
16. J. Christophers, J. Clayton, J. Craske, R. Ward, P. Collins, M. Trowbridge, and G. Darby Survey of resistance of herpes simplex virus to acyclovir in northwest England Antimicrob. Agents Chemother. 42 1998 868 872 (Pubitemid 28216369)
17. J. Christophers, and R.N. Sutton Characterization of acyclovir-resistant and sensitive clinical isolates of herpes simplex virus isolates from an immunocompromised patient J. Antimicrob. Chemother. 20 1987 389 398 (Pubitemid 17140428)
18. D. Coen, and P.A. Schaffer Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1 Proc. Natl. Acad. Sci. U.S.A. 77 1980 2265 2269 (Pubitemid 10093443)
19. J.J. Crute, C.A. Grygon, K.D. Hargrave, B. Simoneau, A-M. Faucher, G. Bolger, P. Kibler, M. Liuzzi, and M.G. Cordingley Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease Nat. Med. 8 2002 386 391 (Pubitemid 34407034)
20. G. Darby, H.J. Field, and S. Salisbury Altered substrate specificity of herpes simplex thymidine kinase confers acyclovir-resistance Nature 289 1981 81 83 (Pubitemid 11178460)
21. M.S. Dodson, and I.R. Lehman Association of DNA helicase and primase activities with a subassembly of the herpes simplex virus 1 helicase-primase composed of the UL5 and UL52 gene products Proc. Natl. Acad. Sci. U.S.A. 88 1991 1105 1109 (Pubitemid 21916173)
22. J.W. Drake, and J.J. Holland Mutation rates among RNA viruses Proc. Natl. Acad. Sci. U.S.A. 96 1999 13910 13913
23. R. Duan, R.D. de Vries, A.D. Osterhaus, L. Remeijer, and G.M. Verjans Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis J. Inf. Dis. 198 2008 659 663
24. H.J. Field Herpes simplex virus antiviral drug resistance - current trends and future prospects J. Clin. Virol. 21 2001 261 269 (Pubitemid 32499236)
25. H.J. Field, and E. De Clercq Antiviral drugs: a short history of their discovery and development Microbiol. Today 31 2004 58 61
26. H.J. Field, and A.M. Thackray Can herpes simplex virus latency be prevented using conventional nucleoside analogue chemotherapy? Antivir. Chem. Chemother. 8 Suppl. 1 1997 59 66
27. H.J. Field, and A.M. Thackray Early therapy with valaciclovir or famciclovir reduces but does not abrogate herpes simplex virus neuronal latency Nucleos. Nucleot. Nucl. Acids 19 2000 461 470 (Pubitemid 30230054)
28. H.J. Field, and P. Wildy The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice Journal of Hygiene, Cambridge 81 1978 267 277 (Pubitemid 9021091)
29. H.J. Field, and R.A. Vere Hodge Antiviral agents B.W. Mahy, M.H.V. Van Regenmortel, Encyclopedia of Virology, I third ed. 2008 Elsevier Oxford pp. 142-154
30. E. Frobert, J.C. Cortay, T. Ooka, F. Najioullah, D. Thouvenot, B. Lina, and F. Morfin Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses Antivir. Res. 79 2008 28 36
31. K. Katsumata, K. Chono, T. Kontani, K. Sudo, Y. Shimizu, and H. Suzuki Efficacy of acute oral treatment with ASP2151 or valacyclovir (VACV) against cutaneous infection with herpes simplex virus (HSV) type 1 in mice Poster V-1742, Interscience Conference on Antimicrobial Agents and Chemotherapy September 12-15, San Francisco, USA 2009
32. H.E. Kaufman, E.D. Varnell, B.M. Gebhardt, H.W. Thompson, E. Atwal, H. Rübsamen-Waigmann, and G. Kleymann Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection J. Ocul. Pharmacol. Ther. 24 2008 34 42 (Pubitemid 351156639)
33. G. Kleymann, R. Fischer, U.A. Betz, M. Hendrix, W. Bender, U. Schneider, G. Handke, P. Eckenberg, G. Hewlett, V. Pevzner, J. Baumeister, O. Weber, K. Henninger, J. Keldenich, A. Jensen, J. Kolb, U. Bach, A. Popp, J. Maben, I. Frappa, D. Haebich, O. Lockhoff, and H. Rubsamen-Waigmann New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease Nat. Med. 8 2002 392 398 (Pubitemid 34407035)
34. R.G. Kost, E.L. Hill, M. Tigges, and S. Straus Recurrent acyclovir-resistant genital herpes in an immunocompetent patient N. Engl. J. Med. 329 1993 1777 1782 (Pubitemid 23355551)
35. B.A. Larder, and G. Darby Selection and characterization of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities Virology 146 1985 262 271 (Pubitemid 16240381)
36. B.A. Larder, Y.C. Cheng, and G. Darby Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1 J. Gen. Virol. 64 1983 523 532 (Pubitemid 13125611)
37. M. Liuzzi, P. Kibler, C. Bousquet, F. Harji, G. Bolger, M. Garneau, N. Lapeyre, R.S. McCollum, A.-M. Faucher, B. Simoneau, and M.G. Cordingley Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase Antivir. Res. 64 2004 161 170 (Pubitemid 39506836)
38. J.T. Matthews, B.J. Terry, and A.K. Field The structure and function of the HSV DNA replication proteins: defining novel antiviral targets Antivir. Res. 20 1993 89 114 (Pubitemid 23024877)
39. D.S. Parris, and J.E. Harrington Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates Antimicrob. Agents Chemother. 22 1982 71 77 (Pubitemid 12029996)
40. R.T. Sarisky, T.H. Bacon, R.J. Boon, K.E. Duffy, K.M. Esser, J. Leary, L.A. Locke, T.T. Nguyen, M.R. Quail, and R. Saltzman Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials Arch. Virol. 148 2003 1757 1769 (Pubitemid 37144179)
41. R.T. Sarisky, T.T. Nguyen, K.E. Duffy, R.J. Wittrock, and J.J. Leary Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2 Antimicrob. Agents Chemother. 44 2000 1524 1529 (Pubitemid 30340789)
42. L.E. Schnipper, and C.S. Crumpacker Resistance of herpes simplex virus to acycloguanosine: role of the viral thymidine kinase and polymerase loci Proc. Natl. Acad. Sci. U.S.A. 77 1980 2270 2273 (Pubitemid 10093444)
43. D.B. Smith, and S.C. Inglis The mutation rate and variability of eukaryotic viruses: an analytical review J. Gen. Virol. 68 1987 2729 2740
44. F.C. Spector, L. Liang, H. Giordano, M. Sivaraja, and M.G. Peterson Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex J. Virol. 72 1998 6979 6987 (Pubitemid 28377824)
45. S. Sukla, S. Biswas, A. Birkmann, P. Lischka, H. Zimmermann, and H.J. Field Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation wth the inhibitor J. Antimicrob. Chemother. 65 2010 1347 1352
46. S. Sukla, S. Biswas, A. Birkmann, P. Lischka, H. Ruebsamen-Schaeff, H. Zimmermann, and H.J. Field Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and HPI-resistant UL5 mutant Antivir. Res. 87 2010 67 73
47. H. Suzuki, K. Chono, K. Katsumata, M. Kobayashi, T. Kontani, K. Sudo, Y. Shimizu, and S. Takakura ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus as well as herpes simplex virus type 1 and 2 Poster V-1741, Interscience Conference on Antimicrobial Agents and Chemotherapy September 12-15, San Francisco, USA 2009
48. S.M. Swetter, E.L. Hill, E.R. Kern, D.M. Koelle, C.M. Posaved, W. Laurence, and S. Safrin Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant thymidine kinase deficient herpes simplex virus J. Inf. Dis. 177 1997 543 550 (Pubitemid 28099865)
49. A. Vere Hodge, and H.J. Field General mechanisms of antiviral resistance B.W. De Clercq, Genetics and Evolution of Infectious Diseases 2010 Elsevier pp. 339-362, Chapter 1
50. S.K. Weller R.M. Sandri-Glowin, HSV-1 DNA Replication in Alphaherpesviruses: Molecular and Cellular Biology Edition 2006 Caister Academic Press
51. L.A. Zhu, and S.K. Weller The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase primase, are essential for its function J. Virol. 66 1992 469 479